JP2009542195A - 可逆的アセチル化によるタンパク質活性の調節方法 - Google Patents

可逆的アセチル化によるタンパク質活性の調節方法 Download PDF

Info

Publication number
JP2009542195A
JP2009542195A JP2009515460A JP2009515460A JP2009542195A JP 2009542195 A JP2009542195 A JP 2009542195A JP 2009515460 A JP2009515460 A JP 2009515460A JP 2009515460 A JP2009515460 A JP 2009515460A JP 2009542195 A JP2009542195 A JP 2009542195A
Authority
JP
Japan
Prior art keywords
acecs2
sirt3
polypeptide
activity
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009515460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009542195A5 (https=
Inventor
ビョルン シュワー
エリック バーディン
Original Assignee
ザ ジェイ． デヴィッド グラッドストーン インスティテューツ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェイ． デヴィッド グラッドストーン インスティテューツ filed Critical ザ ジェイ． デヴィッド グラッドストーン インスティテューツ
Publication of JP2009542195A publication Critical patent/JP2009542195A/ja
Publication of JP2009542195A5 publication Critical patent/JP2009542195A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2009515460A 2006-06-12 2007-06-12 可逆的アセチル化によるタンパク質活性の調節方法 Pending JP2009542195A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81327506P 2006-06-12 2006-06-12
US11/761,198 US8518635B2 (en) 2006-06-12 2007-06-11 Regulation of protein activity by reversible acetylation
PCT/US2007/013804 WO2007149270A2 (en) 2006-06-12 2007-06-12 Regulation of protein activity by reversible acetylation

Publications (2)

Publication Number Publication Date
JP2009542195A true JP2009542195A (ja) 2009-12-03
JP2009542195A5 JP2009542195A5 (https=) 2010-07-29

Family

ID=38833973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515460A Pending JP2009542195A (ja) 2006-06-12 2007-06-12 可逆的アセチル化によるタンパク質活性の調節方法

Country Status (8)

Country Link
US (1) US8518635B2 (https=)
EP (1) EP2029731B1 (https=)
JP (1) JP2009542195A (https=)
AT (1) ATE543902T1 (https=)
AU (1) AU2007261561B2 (https=)
CA (1) CA2654458A1 (https=)
ES (1) ES2380248T3 (https=)
WO (1) WO2007149270A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016536005A (ja) * 2013-09-19 2016-11-24 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｈ３プロファイリングの方法
US10761086B2 (en) 2015-04-27 2020-09-01 Dana-Farber Cancer Institute, Inc. High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
US11215608B2 (en) 2006-03-31 2022-01-04 Dana-Farber Cancer Institute, Inc. Methods of determining cellular chemosensitivity
US11225511B2 (en) 2002-09-09 2022-01-18 Howard Hughes Medical Institute BH3 peptides and methods of use thereof
US11815508B2 (en) 2012-09-19 2023-11-14 Dana-Farber Cancer Institute, Inc. Dynamic BH3 profiling
US12529692B2 (en) 2019-02-26 2026-01-20 Dana-Farber Cancer Institute, Inc. Live cell imaging dynamic BH3 profiling

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122805A1 (en) 2021-12-20 2023-06-29 Vestaron Corporation Sorbitol driven selection pressure method

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US82668A (en) * 1868-09-29 Thomas b
US120008A (en) * 1871-10-17 Improvement in apparatus for feeding pulverized fuel to metallurgical and other furnaces
JP2001149081A (ja) 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
US20020120008A1 (en) 2000-06-29 2002-08-29 Seymour Benzer Life extension of drosophila by a drug treatment
US7241743B2 (en) 2001-06-15 2007-07-10 The Trustees Of Columbia University In The City Of New York Sir2α-based therapeutic and prophylactic methods
US7488587B2 (en) 2001-06-19 2009-02-10 The J. David Gladstone Institutes Histone deacetylase and methods of use thereof
CA2453195A1 (en) 2001-07-06 2003-01-16 Leonard Guarente Sir2 activity
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
CA2417033A1 (en) 2003-01-23 2004-07-23 Paul Kerr External support structure for use in the transporting of manufactured houses
US7272713B1 (en) 2003-10-22 2007-09-18 Symantec Corporation Controlling file operations
US7485416B2 (en) 2003-12-23 2009-02-03 The Regents Of The University Of California Screening methods for the identification of agents that inhibit SIRT1 Tat deacetylase activity

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6012042797; Ｔｈｅ　ＦＡＳＥＢ　Ｊｏｕｒｎａｌ Ｖｏｌ．２０，　Ｎｏ．５, 20060307, ｐ．Ａ９５９ *
JPN6012042798; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｂｉｏｌｏｇｉｃａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．２７６，　Ｎｏ．１４, 2001, ｐ．１１４２０-１１４２６ *
JPN6012042799; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｂｉｏｌｏｇｉｃａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．２８０，　Ｎｏ．１４, 2005, ｐ．１３５６０-１３５６７ *
JPN6012042800; Ｍｏｌｅｃｕｌａｒ　Ｂｉｏｌｏｇｙ　ｏｆ　ｔｈｅ　Ｃｅｌｌ Ｖｏｌ．１６, 2005, ｐ．４６２３-４６３５ *
JPN6012042801; Ｐｒｏｃ　Ｎａｔｌ　Ａｃａｄ　Ｓｃｉ　ＵＳＡ Ｖｏｌ．９９，　Ｎｏ．２１, 2002, ｐ．１３６５３-１３６５８ *
JPN6012042804; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｅｌｌ　Ｂｉｏｌｏｇｙ Ｖｏｌ．１５８，　Ｎｏ．４, 2002, ｐ．６４７-６５７ *
JPN6012042806; Ｐｒｏｃ　Ｎａｔｌ　Ａｃａｄ　Ｓｃｉ　ＵＳＡ Ｖｏｌ．１０３，　Ｎｏ．２７, 20060705, ｐ．１０２３０-１０２３５ *
JPN6012042808; Ｐｒｏｃ　Ｎａｔｌ　Ａｃａｄ　Ｓｃｉ　ＵＳＡ Ｖｏｌ．１０３，　Ｎｏ．２７, 20060705, ｐ．１０２２４-１０２２９ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11225511B2 (en) 2002-09-09 2022-01-18 Howard Hughes Medical Institute BH3 peptides and methods of use thereof
US11215608B2 (en) 2006-03-31 2022-01-04 Dana-Farber Cancer Institute, Inc. Methods of determining cellular chemosensitivity
US11815508B2 (en) 2012-09-19 2023-11-14 Dana-Farber Cancer Institute, Inc. Dynamic BH3 profiling
JP2016536005A (ja) * 2013-09-19 2016-11-24 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｈ３プロファイリングの方法
US10739333B2 (en) 2013-09-19 2020-08-11 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
US11867687B2 (en) 2013-09-19 2024-01-09 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
US10761086B2 (en) 2015-04-27 2020-09-01 Dana-Farber Cancer Institute, Inc. High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
US11867688B2 (en) 2015-04-27 2024-01-09 Dana-Farber Cancer Institute, Inc. High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
US12529692B2 (en) 2019-02-26 2026-01-20 Dana-Farber Cancer Institute, Inc. Live cell imaging dynamic BH3 profiling

Also Published As

Publication number Publication date
US8518635B2 (en) 2013-08-27
WO2007149270A9 (en) 2008-03-06
US20090061015A1 (en) 2009-03-05
EP2029731A4 (en) 2009-10-21
AU2007261561B2 (en) 2013-02-28
WO2007149270A2 (en) 2007-12-27
WO2007149270A3 (en) 2008-10-30
CA2654458A1 (en) 2007-12-27
EP2029731B1 (en) 2012-02-01
AU2007261561A1 (en) 2007-12-27
EP2029731A2 (en) 2009-03-04
ATE543902T1 (de) 2012-02-15
ES2380248T3 (es) 2012-05-09

Similar Documents

Publication Publication Date Title
Nguyen et al. The MARCHF6 E3 ubiquitin ligase acts as an NADPH sensor for the regulation of ferroptosis
Perrone et al. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions
Wang et al. Phosphorylation of ULK1 affects autophagosome fusion and links chaperone-mediated autophagy to macroautophagy
Choi et al. Mechanism of β-adrenergic receptor desensitization in cardiac hypertrophy is increased β-adrenergic receptor kinase
Kim et al. A role for O-GlcNAcylation in setting circadian clock speed
Muñoz-Pinedo et al. Cancer metabolism: current perspectives and future directions
Carnegie et al. AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway
AU2007261561B2 (en) Regulation of protein activity by reversible acetylation
US8367360B2 (en) Method of screening for inhibitors of tau protein phosphororylation by tyrosine kinase c-Abl
US20110218229A1 (en) SIRT1 Modulation of Adipogenesis and Adipose Function
US20110287026A1 (en) Sirt4 and uses thereof
CN101490250A (zh) 通过可逆乙酰化调节蛋白质活性
Reynolds-Peterson et al. Heparan sulfate proteoglycans regulate autophagy in Drosophila
Martins et al. p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes
Liu et al. Fat body-specific reduction of CTPS alleviates HFD-induced obesity
Zhang et al. Oncometabolite 5-IP7 inhibits inositol 5-phosphatase to license E-cadherin endocytosis
US20090258929A1 (en) Compositions and Methods for Modulating mTOR Signaling
Sha et al. The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation
US20080200566A1 (en) Dephosphorylation of HDAC7 By Myosin Phosphatase
EP1907016A2 (en) Methods and composition for modulating foxo1 activity and insulin signaling
Zhao et al. KN-93 promotes HDAC4 nucleus translocation to promote fatty acid oxidation in myocardial infarction
Luo et al. GSK461364 Inhibits NLRP3 Inflammasome by Targeting NEK7 Phosphorylation
US20070026431A1 (en) Modulation of MAPK-mediated phosphorylation and/or FBXW8-mediated ubiquitinylation of cyclin D1 in modulation of cellular proliferation
US20090142335A1 (en) Methods of diagnosis and treatment of metabolic disorders
Zhou et al. Reciprocal Regulation of AMPK-SIRT1 Complex Control of Colorectal Cancer Cell Metastasis by Metformin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121210